knowledge -WSS

knowledge

author：leisure time 2025-09-10 08:41:26 - browse：15811

Matts Take Column Illustration — Molly Ferguson for STAT

The news that the weight loss drug Wegovy reduced the risk of heart attacks and strokes in overweight volunteers opens up the door to vastly expanded use of the drug and medicines like it, known as GLP-1 medicines.

That could have a big, positive impact on public health, and it will very likely swell the coffers of the pharmaceutical companies that make these medicines, including Wegovy’s maker, Novo Nordisk, and Eli Lilly, now the most valuable drug company in history thanks largely to hopes for its GLP-1, Mounjaro. These are medicines that could save lives, make money, and perhaps reshape our culture. But they are also, we are learning, not without risk.

So what’s next?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： FDA's Woodcock to retire early next year

focus

WSS

PBM reforms clear House panel

Surge of respiratory disease in China has likely explanation

Why medical students are struggling with mental health

Why medical students are struggling with mental health

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

How I ended up pumping milk in a bathroom stall at JPM 2024

Wikipedia

knowledge

entertainment

As demand for Covid shots wanes, Moderna seeks its next success

Astellas still sees hope in its gene therapy after four deaths

The cancer drug shortage isn’t new — and neither are the solutions

Doulas covered by Medicaid under New York's new plan

How to save PrEP access — and even expand it

Astellas still sees hope in its gene therapy after four deaths

Medical leaders decry Supreme Court decision on affirmative action

Heart disease and mental health: A look at cardiac psychology

Medical leaders decry Supreme Court decision on affirmative action

Morphosys mixed study results for blood cancer drug

focus

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Astellas still sees hope in its gene therapy after four deaths

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

CRISPR pioneers react to Casgevy, first gene

knowledge

focus

entertainment

leisure time